Al B. Benson III, MD | Northwestern ...

Dr. Al B. Benson

Claim this profile

Northwestern University

Studies Neuroendocrine Tumors
Studies Parotid Gland Cancer
10 reported clinical trials
22 drugs studied

Area of expertise

1Neuroendocrine Tumors
Al B. Benson has run 3 trials for Neuroendocrine Tumors. Some of their research focus areas include:
Stage IV
Stage III
2Parotid Gland Cancer
Al B. Benson has run 2 trials for Parotid Gland Cancer. Some of their research focus areas include:
Stage IV
Stage III
BRAF negative

Affiliated Hospitals

Image of trial facility.
Northwestern University
Image of trial facility.
Northwestern Medicine Lake Forest Hospital

Clinical Trials Al B. Benson is currently running

Image of trial facility.

Triapine + Targeted Radiation

for Neuroendocrine Cancer

This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.
Recruiting1 award Phase 2
Image of trial facility.

Preoperative Chemotherapy + Surgery

for Sarcoma

This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
Recruiting2 awards Phase 35 criteria

More about Al B. Benson

Clinical Trial Related1 year of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Al B. Benson has experience with
  • Lutetium Lu 177 Dotatate
  • Oxaliplatin
  • Preoperative Chemotherapy
  • Surgery
  • Trastuzumab
  • Pertuzumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Al B. Benson specialize in?
Is Al B. Benson currently recruiting for clinical trials?
Are there any treatments that Al B. Benson has studied deeply?
What is the best way to schedule an appointment with Al B. Benson?
What is the office address of Al B. Benson?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security